ArticleMolecular therapy. Nucleic acids2025
Mass photometry as a robust method for characterizing adeno-associated virus critical quality attributes in gene therapy vector.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Analytical Ultracentrifugation for Biopharmaceutical Characterization and Quality Control.International journal of molecular sciences · 2026Review
- Methodological validation of a cryo-TEM-based detection method for empty capsid ratio in recombinant adeno-associated virus.Biochemistry and biophysics reports · 2026Article
- Plasmonic Nanopore Sensing to Probe the DNA Loading Status of Adeno-Associated Viruses.Chemosensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of adeno-associated viruses (AAVs) as gene therapy vectors is growing, resulting in a pressing need for efficient, reliable AAV analysis methods. Characterizing AAV critical quality attributes (CQAs), such as the abundance of empty or partially filled capsids, is paramount for developing and producing products with high efficacy, low immunogenicity, and low cost. Available methods include analytical ultracentrifugation (AUC)-considered one of the gold standards of AAV analysis technique-and mass photometry-a newer method based on single-particle light scattering. Mass photometry is a fast, low-cost tool that uses little sample and is suitable for environments requiring good manufacturing practices (GMP) compliance. Here, we assess mass photometry's performance in AAV characterization by using it to analyze a sample of empty AAVs, to measure proportions of empty vs. partially filled vs. full AAVs, to quantify loading in samples ranging from 100% empty to nearly 100% loaded, and to measure samples containing transgenes of different lengths. Comparing to AUC data where appropriate, we find that the two methods give comparable results. Based on its accuracy, precision, measurement capabilities, and practical advantages (e.g., speed and low cost), we conclude that mass photometry is an ideal AAV analysis tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.